S100 Protein Family in Lung Cancer: an Updated Narrative Review
Open Access
- 1 March 2025
- journal article
- review article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 17, 713-722
Abstract
The S100 protein family comprises 25 known members that modulate variously basic biological behaviors of cells by binding Ca2+ and activating Ca2+-signaling pathways. As the primary cause of cancer-related death, lung cancer is closely associated with several S100 proteins, like S100A2, S100A4, S100A6, S100A8/9, etc. Notably, the functions and mechanisms of different S100 proteins vary in every sub-type of lung cancer. Overall speaking, the abnormal expression of S100 proteins is predominantly observed in lung adenocarcinoma, while their roles are limited in small-cell lung cancer. This review, which presents an update on our previously published review of S100 proteins in lung cancer (2021), aims to enable readers having a deeper understanding of the roles of different S100 proteins in three main sub-types of lung cancer, as well as to facilitate their future researches. It focuses on relevant studies examining the functions of S100 proteins in lung adenocarcinoma, squamous carcinoma, and small-cell lung cancer. This review was conducted based on this standard, and provides a comprehensive evaluation of the literature review on S100 proteins as well as enhances understanding of the relationship between S100 proteins and every sub-type of lung cancer from a new perspective.Keywords
This publication has 74 references indexed in Scilit:
- Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancerLung Cancer, 2009
- Molecular regulation of S100P in human lung adenocarcinomasInternational Journal of Molecular Medicine, 2008
- Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomasThorax, 2008
- S100A2–S100P expression profile and diagnosis of non-small cell lung carcinoma: Impairment by advanced tumour stages and neoadjuvant chemotherapyEuropean Journal of Cancer, 2007
- Poor outcome of patients with pulmonary adenocarcinoma showing decreased E-cadherin combined with increased S100A4 expressionInternational Journal of Oncology, 2006
- Differential expression of S100A2 and S100A4 in lung adenocarcinomas: Clinicopathological significance, relationship to p53 and identification of their target genesCancer Science, 2005
- Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancerInternational Journal of Cancer, 2005
- S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomasBritish Journal of Cancer, 2004
- Immunohistochemical investigation of S100A9 expression in pulmonary adenocarcinoma: S100A9 expression is associated with tumor differentiationOncology Reports, 2001
- Chromatographic and Electrophoretic Fractionation of Soluble Proteins of Brain and LiverJournal of Biological Chemistry, 1965